DCAF7: A Potential Drug Target and Biomarker (G10238)

Target Name: DCAF7

NCBI ID: G10238

DCAF7

DCAF7: A Potential Drug Target and Biomarker

Drug-resistant bacterial infections are a major public health concern, resulting in significant morbidity and economic costs. The bacteria that cause these infections are often highly resistant to conventional antibiotics, making them difficult to treat. This has led to a need for new approaches to treat bacterial infections.

One potential approach to treating bacterial infections is to target the bacterial efflux pumps. Efficacy of antibiotics is often limited by the bacteria's ability to produce efflux pumps, which allow the bacteria to expel antibiotics from their cells. The DCAF7 gene has been identified as a potential drug target for treating bacterial efflux pump-mediated infections.

The DCAF7 gene

The DCAF7 gene is located on the X chromosome and encodes a protein known as DCAF7. DCAF7 is a member of the P-type ATPase (P-ATPase) family, which is a common type of transmembrane protein that is involved in a variety of cellular processes, including ion and water transport, and energy production.

In bacteria, DCAF7 is involved in the production of efflux pumps. These pumps are responsible for pumping antibiotics out of the bacterial cells, making the bacteria more resistant to antibiotics. DCAF7 is a critical gene for the production of efflux pumps, which are a major factor in the development of drug-resistant bacterial infections.

DCAF7 as a drug target

DCAF7 has been identified as a potential drug target for treating bacterial efflux pump-mediated infections. By inhibiting the activity of DCAF7, it is possible to reduce the production of efflux pumps and improve the effectiveness of antibiotics.

DCAF7 has been shown to be involved in the production of efflux pumps in various bacterial species, including Staphylococcus aureus and Pseudomonas aeruginosa. In these species, DCAF7 is involved in the production of the type I efflux pump, which is responsible for pumping out of the cell a wide variety of antibiotics, including ??-lactam antibiotics.

DCAF7 has also been shown to be involved in the production of the type II efflux pump, which is responsible for pumping out of the cell antibiotics such as ciprofloxacin and quinolones.

DCAF7 as a biomarker

DCAF7 has also been shown to be involved in the regulation of bacterial growth and metabolism. In various bacterial species, DCAF7 is involved in the production of the bacterial flagellum, which is responsible for the bacterial's movement.

Additionally, DCAF7 has been shown to be involved in the production of the bacterial cell wall, which is responsible for maintaining the structural integrity of the cell.

Conclusion

In conclusion, DCAF7 is a potential drug target for treating bacterial efflux pump-mediated infections. By inhibiting the activity of DCAF7, it is possible to reduce the production of efflux pumps and improve the effectiveness of antibiotics. Further research is needed to determine the exact mechanism of DCAF7's involvement in the production of efflux pumps and to develop new treatments based on this potential drug target.

Protein Name: DDB1 And CUL4 Associated Factor 7

Functions: Involved in craniofacial development. Acts upstream of the EDN1 pathway and is required for formation of the upper jaw equivalent, the palatoquadrate. The activity required for EDN1 pathway function differs between the first and second arches (By similarity). Associates with DIAPH1 and controls GLI1 transcriptional activity. Could be involved in normal and disease skin development. May function as a substrate receptor for CUL4-DDB1 E3 ubiquitin-protein ligase complex

The "DCAF7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DCAF7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets